New Zealand Premarket Pathway: Four Statutory Actions, No Registration Certificate

Regulatory information verified as of October 29, 2026.

1. Key takeaways

There is no review step anywhere in the New Zealand market pathway for medical devices. After verifying the official provisions line by line, GRZAN confirms that a complete pathway consists of four statutory actions — product qualification, Sponsor (New Zealand sponsor) appointment, risk classification and WAND notification — with no pre-market approval, no documentation review, and no registration certificate or market authorisation of any kind.

The only hard deadline on the pathway is written in regulation 6 of the Medicines (Database of Medical Devices) Regulations 2003 (SR 2003/325): the Sponsor must, within 30 working days after becoming the sponsor of the device, ensure the required information reaches the Director-General or the person maintaining the database on the Director-General’s behalf, and provide a declaration complying with regulation 7. Medsafe’s page expresses it as 30 calendar days. The notification itself is free of charge, with no ongoing fees.

The sequence is the reverse of most markets: New Zealand operates on an arrive-first, notify-later basis. The obligation only starts to run once the device has arrived and the Sponsor identity has arisen, not before shipment under a licence — consistent with the Medicines Act 1981 (1981 No 118), which has no device pre-market approval provision. The true cost lies at the back end: once a device is supplied, the Sponsor immediately carries safety obligations under s 38 of the Medicines Act 1981, the 10 working day correction duty under regulation 8, recall and adverse event reporting duties, and labelling obligations under regulation 12(4) of the Medicines Regulations 1984 (SR 1984/143). Breach of any of regulations 6, 8, 9 or 10 of SR 2003/325 is an offence punishable on conviction by a fine not exceeding NZ$500.

• Product qualification under s 3A and s 4 of the Medicines Act 1981.
• Exemption screening against the nine categories of Schedule 1 of SR 2003/325.
• Sponsor identification under reg 3.
• WAND entry and declaration under regs 5 and 7.

2. Legal basis

Official sources: https://www.legislation.govt.nz/regulation/public/2003/0325/latest/ ; https://www.medsafe.govt.nz/regulatory/DevicesNew/3WAND.asp ; https://www.medsafe.govt.nz/regulatory/DevicesNew/3-6RegulatoryRequirements.asp

3. Expert insights

Insight 1: the six nodes of the complete pathway. GRZAN breaks the official requirements into six nodes. Node one is product qualification under s 3A and s 4 of the Medicines Act 1981. Node two is exemption screening against the nine situations in Schedule 1 of SR 2003/325; a hit removes the notification obligation entirely. Node three is identifying the Sponsor under reg 3 — who imports, exports or manufactures the device in New Zealand. Node four is classification: the 22 rules of Schedule 2 fix the risk class, and a GMDN code must be obtained. Node five is the WAND entry and declaration under regs 5 and 7. Node six is the post-market loop: corrections under reg 8, recalls, adverse event reporting and label maintenance.

Insight 2: the clock starts on identity, not on a licence. The only deadline on the pathway runs from becoming the Sponsor, not from obtaining any approval. The reg 3 definition of Sponsor is a set of factual states — who imports or arranges import, exports or arranges export, or manufactures or arranges manufacture of the device in New Zealand. Once ownership and logistics arrangements occur, the identity arises and the clock starts. Regulation 6 says 30 working days; Medsafe’s Regulatory Requirements for Sponsors page adds that the period runs from the date the device first arrives in New Zealand, while its WAND home page says 30 calendar days. GRZAN quotes the statutory wording externally and schedules internally against the stricter side. Notification happens after arrival by design, so it cannot be read backwards as failure-to-notify-equals-unlawful-supply, and exempt devices never notify at all.

Insight 3: the endpoint is a record to maintain, not a certificate. WAND is not an approval system; Medsafe has officially stated that notification does not mean it has assessed the quality, safety, efficacy or performance of the product. The endpoint is therefore not something you obtain but something you continuously maintain. Reg 9 requires the Sponsor to establish the procedures necessary for ongoing compliance with regs 5, 6 and 8 — easily overlooked, because it turns notification from a one-off act into a standing obligation.

Insight 4: the pre-market and post-market burden is asymmetric. The front end is nearly barrier-free; the back end is densely loaded. Sections 38(2)–(3) of the Medicines Act 1981 empower the Director-General to require an importer or manufacturer to supply safety evidence within 45 days, and s 38(8) punishes selling before the requirement is met with up to 6 months imprisonment or a NZ$5,000 fine — far above the NZ$500 fine under reg 14, showing that New Zealand places its enforcement weight on after-the-fact accountability.

4. Practical recommendations

• GRZAN recommends running the pathway map in reverse before any supply begins: start from the notification fields and work back to the GMDN code, risk classification, Sponsor entity and exemption screening, so gaps are not found after the goods reach port.
• GRZAN turns Sponsor identification into a written determination recording the legal basis (which limb of reg 3), the determination date and the supporting documents — evidence of when the reg 6 clock started and the baseline for judging later reg 8 corrections.
• Every Schedule 1 exemption claim must be documented: a wrong call means the reg 6 duty is skipped, the offence under reg 14 requires no proof of intent, and s 80 of the Medicines Act 1981 provides that the prosecution need not prove mens rea.
• Do not close the project once notification is complete: build a reg 9 change-monitoring procedure capturing manufacturer and Sponsor name changes and lapsed certifications, which trigger the 10 working day correction duty under reg 8.
• Reg 10 prohibits statements suggesting, directly or indirectly, that entry in the database means the Director-General or the Ministry of Health endorses the product’s safety or suitability — keep such wording out of promotional material.

5. Verification checklist

• □ Product qualified as a device under s 3A and s 4 of the Medicines Act 1981, determination on record
• □ Exclusion assessed against the nine exemption categories of Schedule 1 of SR 2003/325
• □ Sponsor (New Zealand sponsor) identified under reg 3, with a registered office or principal place of business in New Zealand
• □ Risk class determined under the 22 rules of Schedule 2, with a traceable trail
• □ GMDN code and description obtained; IVDs carry a 5-digit code
• □ All reg 5 information complete; Class III and AIMD devices have a unique product identifier
• □ Entry and the reg 7 declaration completed within 30 working days of Sponsor status
• □ Procedures under reg 9 established, covering regs 5, 6 and 8
• □ Labels comply with reg 12(4) of the Medicines Regulations 1984
• □ Promotional material screened against the prohibited statements of reg 10

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the New Zealand market. Our team manages WAND entries and sponsor registration, prepares reference-market evidence, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com